Back to results
US 2017/0281577 A1Published application
Treatment of cancer with specific rxr agonists
AssigneeIo Therapeutics, Inc.
InventorRoshantha A. Chandraratna
Life of this patent
Estimating the term…
Abstract
A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
Claims15
A method of treating a hematologic malignancy comprising administering to a patient in need of such treatment a retinoid X receptor (RXR) agonist at a dose below the Retinoic Acid Receptor (RAR) activating threshold and at or above the RXR effective dose, the RXR agonist has the chemical structure
- where R is H, lower alkyl or 1 to 6 carbons, or a pharmaceutically acceptable salt of the compound, and the dose of the RXR agonist is from about 0.01 to about 100 mg/m2/day.
Dependencies are inferred from the claim text.